Influenza virus vaccine, live, trivalent Disease Interactions
There are 3 disease interactions with influenza virus vaccine, live, trivalent:
Influenza Vaccine (Includes Influenza virus vaccine, live, trivalent) ↔ Gbs
Severe Potential Hazard, Moderate plausibility
Applies to: Guillain-Barre Syndrome
The use of influenza vaccine has been associated with an elevated risk of Guillain-Barré syndrome (GBS). It is not recommended to administer this vaccine if GBS has occurred within 6 weeks following previous influenza vaccination. Care and close monitoring is recommended and consideration of the potential benefits and risks should be assessed.
Vaccination (Includes Influenza virus vaccine, live, trivalent) ↔ Infections
Severe Potential Hazard, High plausibility
Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Fever
Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.
- "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
- "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
Intranasal Influenza Vaccine (Includes Influenza virus vaccine, live, trivalent) ↔ Asthma
Moderate Potential Hazard, Moderate plausibility
Applies to: Asthma
Intranasal influenza vaccine has been associated with increased wheezing. Caution is recommended when using intranasal influenza vaccine in children with recurrent wheezing and asthmatic patients as these patients may be at an increased risk of developing wheezing.
influenza virus vaccine, live, trivalent drug Interactions
There are 329 drug interactions with influenza virus vaccine, live, trivalent
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.